{Reference Type}: Journal Article
{Title}: End-on PEGylation of heparin: Effect on anticoagulant activity and complexation with protamine.
{Author}: Amaral S;Lozano-Fernández T;Sabin J;Gallego A;da Silva Morais A;Reis RL;González-Fernández Á;Pashkuleva I;Novoa-Carballal R;
{Journal}: Int J Biol Macromol
{Volume}: 249
{Issue}: 0
{Year}: 2023 Sep 30
{Factor}: 8.025
{DOI}: 10.1016/j.ijbiomac.2023.125957
{Abstract}: Heparin is the most common anticoagulant used in clinical practice but shows some downsides such as short half-life (for the high molecular weight heparin) and secondary effects. On the other hand, its low molecular weight analogue cannot be neutralized with protamine, and therefore cannot be used in some treatments. To address these issues, we conjugated polyethylene glycol (PEG) to heparin reducing end (end-on) via oxime ligation and studied the interactions of the conjugate (Hep-b-PEG) with antithrombin III (AT) and protamine. Isothermal titration calorimetry showed that Hep-b-PEG maintains the affinity to AT. Dynamic light scattering demonstrated that the Hep-b-PEG formed colloidal stable nanocomplexes with protamine instead of large multi-molecular aggregates, associated with heparin side effects. The in vitro (human plasma) and in vivo experiments (Sprague Dawley rats) evidenced an extended half-life and higher anticoagulant activity of the conjugate when compared to unmodified heparin.